| Overview |
| bs-11321R-Cy5 |
| Islet 2 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Islet 2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Nucleus |
| Insulin gene enhancer protein ISL 2; Insulin gene enhancer protein ISL-2; Insulin gene enhancer protein ISL2; ISL 2; ISL 2 transcription factor; ISL 2 transcription factor LIM/homeodomain; ISL2; ISL2 transcription factor; ISL2 transcription factor LIM/homeodomain; ISL2_HUMAN; Islet-2; Islet2; FLJ10160. |
| Islet-2 (insulin gene enhancer protein ISL-2) is a 359 amino acid protein encoded by the human gene ISL2. Islet-2 is a nuclear protein that contains two N-terminal LIM domains, followed by a homeodomain and a serine/ glutamine/threonine-rich C-terminus. Islet-2 is a transcriptional factor that defines subclasses of motor neurons that segregate into columns in the spinal cord and select distinct axon pathways. Islet-1 and Islet-2 are initially ex-pressed by all postmitotic spinal motor neurons prior to diversification of somatic and visceral neuronal fates. Somatic, but not visceral, motor neurons maintain Islet-2 expression at later embryonic stages. An early phase of Islet-2 expression by prospective visceral motor neurons of the sympathetic preganglionic motor column is critical for the emergence of complete visceral motor neuron character. Mutations that reduce or eliminate both Islet-1 and Islet-2 activity will result in pronounced defects in visceral motor neuron generation and eroded somatic motor neuron character. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz